Randomized trial · people
Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg arm
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this 48-week trial, weight loss with retatrutide grew with dose, gut side effects were the most common, and a lower starting dose partly eased them.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 338
- Published
- 2023
- Journal
- N Engl J Med
What they tested
The team wanted to learn how different weekly doses of retatrutide relate to weight loss, side effects and safety in adults with obesity.
How the study was done
A phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with a BMI (body-mass index, weight relative to height) of 30 or higher, or 27 to under 30 with at least one weight-related condition. Participants got a weekly shot under the skin of retatrutide at 1 mg, 4 mg, 8 mg or 12 mg (some arms started at a lower dose) or placebo, a dummy shot, for 48 weeks.

Model. Individual results vary.
What they found
At 24 weeks, the main goal, average body weight changed by -7.2% in the 1 mg arm, -12.9% in the combined 4 mg arms, -17.3% in the combined 8 mg arms and -17.5% in the 12 mg arm, compared with -1.6% on placebo. At 48 weeks, the changes were -8.7%, -17.1%, -22.8% and -24.2%, compared with -2.1% on placebo. By 48 weeks, a loss of 15% or more was seen in 60% of the 4 mg group, 75% of the 8 mg group and 83% of the 12 mg group, compared with 2% on placebo. Stomach and gut side effects were the most common, rose with dose, were mostly mild to moderate and were partly eased by starting at 2 mg instead of 4 mg. Heart rate also went up with dose, peaked at 24 weeks and then came down.
What it doesn’t show
This was a mid-stage trial of 338 people lasting 48 weeks, so it doesn't show longer-term results or rarer side effects. It was funded by Eli Lilly.
The paper
Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.